Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Cytek Biosciences (CTKB) Accumulated Depreciation & Amortization (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 5.09% year-over-year to $7.6 million, compared with a TTM value of $7.6 million through Dec 2025, up 5.09%, and an annual FY2025 reading of $7.6 million, up 5.09% over the prior year.
  • Accumulated Depreciation & Amortization was $7.6 million for Q4 2025 at Cytek Biosciences, up from $5.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $7.6 million in Q4 2025 and bottomed at $1.0 million in Q1 2023.
  • Average Accumulated Depreciation & Amortization over 5 years is $3.6 million, with a median of $3.1 million recorded in 2023.
  • The sharpest move saw Accumulated Depreciation & Amortization surged 155.17% in 2023, then rose 5.09% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $1.2 million in 2021, then soared by 100.64% to $2.5 million in 2022, then surged by 142.7% to $6.0 million in 2023, then rose by 19.25% to $7.2 million in 2024, then increased by 5.09% to $7.6 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for CTKB at $7.6 million in Q4 2025, $5.7 million in Q3 2025, and $3.8 million in Q2 2025.